scholarly journals Clinical use of glucose sensors in the treatment of diabetes in children and adolescents

2003 ◽  
Vol 20 (1) ◽  
pp. 7-12 ◽  
Author(s):  
J Ludvigsson ◽  
E Isacson
Keyword(s):  
Children And Adolescents ◽  
Glucose Sensors ◽  
Clinical Use ◽  
Treatment Of Diabetes

Biguanides reassessed

1969 ◽  
Vol 7 (2) ◽  
pp. 7-8
Keyword(s):  
Clinical Use ◽  
Treatment Of Diabetes

The biguanides phenformin (Dibotin - Bayer) and metformin (Glucophage - Rona) have been used in the treatment of diabetes for about 10 years. Continuing experience and many new observations have gradually led to changes in their clinical use.

scholarly journals Pharmacokinetic Variability and Clinical Use of Lacosamide in Children and Adolescents in Denmark and Norway

2019 ◽  
Vol 41 (3) ◽  
pp. 340-347 ◽  
Author(s):  
Margrete Larsen Burns ◽  
Marina Nikanorova ◽  
Arton Baftiu ◽  
Jan Borg Rasmussen ◽  
Svein I. Johannessen ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Clinical Use ◽  
Pharmacokinetic Variability

scholarly journals Lantus, the first peakless basal insulin analogue: 10 years of clinical experience in children and adolescents

2014 ◽  
Vol 17 (2) ◽  
pp. 105-115
Author(s):  
Tamara Leonidovna Kuraeva
Keyword(s):  
Glycemic Control ◽  
Children And Adolescents ◽  
Insulin Analogue ◽  
Vascular Complications ◽  
Clinical Use ◽  
Age Group ◽  
Safety And Efficacy ◽  
Glycemic Profile

This review analyses existing literature, including authors' own data, describing the results of clinical trials which assess safety and efficacy of insulin Glargine (Lantus?) in children and adolescents, as well as peculiar features of T1D management in this age group, including the challenge of reducing the rate of hypoglycemia while maintaining adequate glycemic control. The article also discusses various issues in T1D management in children and adolescents, including the role of glycemic control in development of vascular complications, hypoglycemia and the variability of glycemia. The data confirm the high efficacy of Lantus insulin in respect to metabolic control, including the decrease in the incidence of hypoglycemia and in variability of glycemic profile, the safety of its clinical use in treatment of children, including young children, and adolescents, as well as its ability to improve the quality of life for patients and their parents.

scholarly journals A Review of Clinical Experience with Newer Antifungals in Children

2008 ◽  
Vol 13 (3) ◽  
pp. 124-140
Author(s):  
Renee M. Fallon ◽  
Jennifer E. Girotto
Keyword(s):  
Children And Adolescents ◽  
21St Century ◽  
Antifungal Agents ◽  
Fungal Infections ◽  
Pediatric Population ◽  
Pharmacokinetic Data ◽  
Clinical Use ◽  
Clinical Experiences ◽  
Key Concepts ◽  
Pediatric Pharmacology

Fungal infections are a significant cause of morbidity and mortality in immunocompromised children. Since the beginning of the 21st century, many new antifungals including the echinocandins (i.e., caspofungin, micafungin, anidulafungin) and the newer generation triazoles (i.e., voriconazole and posaconazole) have received Food and Drug Administration approval. Unfortunately, despite making great strides in the adult arena, these agents are not currently approved in the pediatric population. However, pharmacokinetic data and clinical experiences with these agents in infants, children, and adolescents are mounting. As such, this review will discuss key concepts in pediatric pharmacology and clinical use of these newer antifungal agents.

scholarly journals Use of metformin in pediatric type 2 diabetes

2013 ◽  
Vol 20 (4) ◽  
pp. 435-439
Author(s):  
Diana Paun ◽  
Alexandra Bulgar
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Insulin Secretion ◽  
Environmental Factors ◽  
Children And Adolescents ◽  
Clinical Use ◽  
Pancreatic Insulin ◽  
Prevalence Of Obesity ◽  
Genetic And Environmental Factors

Abstract In the last 10 years the incidence of type 2 diabetes (T2DM) in children and adolescents has increased, due to increasing prevalence of obesity in youth. Therefore, the prevalence of diabetes-related complications such as hypertension, hyperlipidemia and microalbuminuria has also increased in pediatric T2DM. The pathogenesis of T2DM in children involves genetic and environmental factors that will determine the increase of insulin resistance and decrease of beta pancreatic insulin secretion. Only metformin and insulin are approved for clinical use in children in the majority of countries. The aim of this paper is to review the benefits of the treatment with metformin in children and adolescents with T2DM.

Sign in / Sign up

Export Citation Format

Share Document